Oncocytic adenocarcinoma of the stomach: Parietal cell carcinoma

Mardi, Kavita

doi:10.4103/0973-1482.110354

J Can Res Ther

2013

DOI: 10.4103/0973-1482.110354

|View full text |Cite

Oncocytic adenocarcinoma of the stomach: Parietal cell carcinoma

Kavita Mardi

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2021

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2e4 Commonly, immunohistochemical stains for antimitochondrial antibodies are strongly positive. 2,3 The ultrastructural features of tumour cells correspond to an 'oncocytic cytoplasm' with abundant mitochondria, tubulovesicles, intercellular lumina filled with undulating microvilli and intracellular canaliculi. 2e5 In 2002 Takubo et al presented 10 cases of gastric adenocarcinoma with morphological features similar to those of parietal cell carcinoma, however immunohistochemical staining of the tumours with four different antiparietal cell antibodies (anti-H þ -K þ -adenosine triphoshatase antibodies) was negative in all cases.…”

mentioning

confidence: 99%

Parietal cell/oncocytic/mitochondrion-rich gastric carcinoma: a need for clarity in terminology

Mavroeidis¹,

Saffioti²

2021

Pathology

View full text Add to dashboard Cite

specific differentiation. 1,10 Therefore in 2012, Stockman et al. first designated the distinct entity as 'malignant gastrointestinal neuroectodermal tumour'. 1 According to available current data, the biological behaviour of malignant GNET is highly malignant and almost all of the reported cases followed an aggressive clinical course with local recurrence in the short term, and metastasis to lymph nodes or hematogenous spread early or even at initial diagnosis. However, our case presented an indolent clinical course. The patient had evidence of the tumour from the age of 37, which progressed slowly for 10 years without any medical intervention. After excision of the tumour, the patient was alive without evidence of disease for 8 months. Interestingly, Prado et al. have reported one case of indolent GNET of the colon which also had a 10 year long clinical course. 11 Our case still needs further follow-up observation to evaluate long-term outcome.

show abstract

mentioning

confidence: 99%

Parietal cell/oncocytic/mitochondrion-rich gastric carcinoma: a need for clarity in terminology

Mavroeidis¹,

Saffioti²

2021

Pathology

View full text Add to dashboard Cite

show abstract

Gastric Adenocarcinoma of the Fundic Gland Type

Benedict

Lauwers

Jain

2018

American Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

Parietal cell/oncocytic gastric carcinoma: systematic review and first-time assessment of HER2 status in two new cases

Saffioti

et al. 2020

annals

View full text Add to dashboard Cite

Introduction Parietal cell/oncocytic gastric carcinomas are very rare and various aspects of this group remain unclear. The human epithelial growth factor receptor 2 (HER2) status of these tumours is largely unknown. Methods We performed a systematic electronic search of the literature and clinicopathological presentation of two cases including first-time complete assessment of HER2 status. Thirty-two patients with a mean age of 64.3 years, 87.5% of whom were male, were included in this review. Findings Half of the cases were recorded in Asia. Median follow-up was 24 months. There was no predominant site of development, while underlying histological abnormalities were present in 25%. At initial presentation, lymph node involvement was evident in 46.6% while distant metastatic disease was present in 9.3%. Presentation at stage I occurred in 55.6%. Potentially curative surgical/interventional treatment was intended in 90.6%. Recurrence occurred in 6.6%, while death was recorded in 19.2%, with cancer-related deaths reaching 11.5%. The one- and three-year survival rates were 84.2% and 79%, respectively. Our two cases displayed negative HER2 expression. Conclusions This systematic review demonstrates that this group of malignancies is very rare but possibly underdiagnosed. The disease commonly presents at early stage, mainly affecting middle-aged men. The prognosis is generally favourable even in cases of advanced disease. The HER2 expression and its correlation with the outcomes need to be further explored.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Oncocytic adenocarcinoma of the stomach: Parietal cell carcinoma

Cited by 3 publications

References 4 publications

Parietal cell/oncocytic/mitochondrion-rich gastric carcinoma: a need for clarity in terminology

Parietal cell/oncocytic/mitochondrion-rich gastric carcinoma: a need for clarity in terminology

Gastric Adenocarcinoma of the Fundic Gland Type

Parietal cell/oncocytic gastric carcinoma: systematic review and first-time assessment of HER2 status in two new cases

Contact Info

Product

Resources

About